Published in Vaccine on July 01, 2008
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clin Cancer Res (2014) 0.93
Therapeutic HPV DNA vaccines. Expert Rev Vaccines (2009) 0.90
DNA vaccines for cervical cancer. Am J Transl Res (2010) 0.88
Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine (2009) 0.86
Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers. Biomed Res Int (2014) 0.84
DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia. PLoS One (2012) 0.83
Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. J Biomed Sci (2010) 0.83
Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Gene Ther (2009) 0.80
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int (2013) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03
DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol (2000) 4.51
Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene (2001) 3.44
Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity (1997) 3.33
A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol (1989) 3.00
Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res (2000) 2.91
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest (2001) 2.61
DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23
Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A (1992) 2.10
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87
Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol (2005) 1.77
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol (1999) 1.57
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
DNA vaccines. Life Sci (1997) 1.53
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther (2003) 1.45
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol Biol (2008) 1.12
Human papillomavirus and other risk factors for cervical cancer. Biomed Pharmacother (1997) 1.04
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol (2007) 0.98
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol (2005) 0.96
Testicular germ cell sensitivity to TRAIL-induced apoptosis is dependent upon p53 expression and is synergistically enhanced by DR5 agonistic antibody treatment. Apoptosis (2006) 0.93
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol (2008) 0.89
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol (2007) 0.87
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res (2010) 3.40
New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol (2005) 3.23
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J (2003) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo. J Exp Med (2007) 2.82
Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood (2002) 2.72
Tumor necrosis factor alpha (TNFalpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNFalpha. J Biol Chem (2005) 2.71
TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem (2003) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res (2005) 2.53
Retracted FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest (2011) 2.44
Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest (2011) 2.40
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Longitudinal care improves disclosure of psychosocial information. Arch Pediatr Adolesc Med (2003) 2.29
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol (2011) 2.27
Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood (2009) 2.27
OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med (2003) 2.26
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood (2005) 2.21
Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol (2003) 2.16
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A (2011) 2.08
Activation of NK cell cytotoxicity. Mol Immunol (2005) 2.03
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol (2013) 2.01
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer (2009) 1.98
The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem (2005) 1.96
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci (2009) 1.95
NKT cells - conductors of tumor immunity? Curr Opin Immunol (2002) 1.94
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med (2007) 1.93
Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity (2004) 1.93
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. J Immunol (2010) 1.91
Phosphorylation of serine 276 is essential for p65 NF-kappaB subunit-dependent cellular responses. Biochem Biophys Res Commun (2003) 1.91
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Joint Modeling and Estimation for Recurrent Event Processes and Failure Time Data. J Am Stat Assoc (2004) 1.87
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med (2003) 1.85
Effects of improved access to safety counseling, products, and home visits on parents' safety practices: results of a randomized trial. Arch Pediatr Adolesc Med (2002) 1.83
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Nature's TRAIL--on a path to cancer immunotherapy. Immunity (2003) 1.77
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol (2006) 1.77
Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol (2005) 1.76
Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Protection from endogenous perforin: glycans and the C terminus regulate exocytic trafficking in cytotoxic lymphocytes. Immunity (2011) 1.73
Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol (2007) 1.73
TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J (2006) 1.73
RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol (2009) 1.73
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. Eur J Immunol (2003) 1.69
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol (2013) 1.66
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol (2002) 1.65
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death. J Biol Chem (2002) 1.61
B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism. J Immunol (2004) 1.61
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res (2012) 1.59
Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58